In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Brought to you by

Series A-1 brings in $6.8mm for Cerecor

27 Sep 2013

Executive Summary

Cerecor Inc. (neurology and respiratory therapeutics) raised $6.8mm through its Series A-1 preferred stock financing to 146 undisclosed investors. The company will use the funds to complete the technology transfer of CERC301 (a Phase II-ready selective NR2B antagonist for depression) and the COMT platform from Merck & Co. Inc. Cerecor has raised $30mm since its 2011 inception.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Specialty Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies

UsernamePublicRestriction

Register

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By